Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer

An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial

A. J. Duffield-Lillico, B. L. Dalkin, M. E. Reid, B. W. Turnbull, E. H. Slate, Elizabeth T Jacobs, J. R. Marshall, L. C. Clark

Research output: Contribution to journalArticle

388 Citations (Scopus)

Abstract

OBJECTIVE: To present the results (to January 1996, the end of blinded treatment) of the Nutritional Prevention of Cancer (NPC) Trial, a randomized trial of selenium (200 μg daily) designed to test the hypothesis that selenium supplementation (SS) could reduce the risk of recurrent nonmelanoma skin cancer among 1312 residents of the Eastern USA. MATERIALS AND METHODS: Original secondary analyses of the NPC to 1993 showed striking inverse associations between SS and prostate cancer incidence. A subsequent report revealed that this effect was accentuated among men with the lowest baseline plasma selenium concentrations. The effects of treatment overall and within subgroups of baseline prostate-specific antigen (PSA) and plasma selenium concentrations were examined using incidence rate ratios and Cox proportional hazards models. RESULTS: SS continued to significantly reduce the overall incidence (relative risk and 95% confidence interval) of prostate cancer (0.51, 0.29-0.87). The protective effect of SS appeared to be confined to those with a baseline PSA level of ≤4 ng/mL (0.35, 0.13-0.87), although the interaction of baseline PSA and treatment was not statistically significant. Participants with baseline plasma selenium concentrations only in the lowest two tertiles (< 123.2 ng/mL) had significant reductions in prostate cancer incidence. A significant interaction between baseline plasma selenium and treatment was detected. CONCLUSION: To the end of the blinded treatment the NPC trial continued to show a significant protective effect of SS on the overall incidence of prostate cancer, although the effect was restricted to those with lower baseline PSA and plasma selenium concentrations.

Original languageEnglish (US)
Pages (from-to)608-612
Number of pages5
JournalBJU International
Volume91
Issue number7
DOIs
StatePublished - May 2003

Fingerprint

Selenium
Prostatic Neoplasms
Incidence
Neoplasms
Prostate-Specific Antigen
Therapeutics
Skin Neoplasms
Proportional Hazards Models
Confidence Intervals

Keywords

  • Chemoprevention
  • Incidence
  • Prostate cancer
  • PSA
  • Risk
  • Selenium

ASJC Scopus subject areas

  • Urology

Cite this

Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer : An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. / Duffield-Lillico, A. J.; Dalkin, B. L.; Reid, M. E.; Turnbull, B. W.; Slate, E. H.; Jacobs, Elizabeth T; Marshall, J. R.; Clark, L. C.

In: BJU International, Vol. 91, No. 7, 05.2003, p. 608-612.

Research output: Contribution to journalArticle

Duffield-Lillico, A. J. ; Dalkin, B. L. ; Reid, M. E. ; Turnbull, B. W. ; Slate, E. H. ; Jacobs, Elizabeth T ; Marshall, J. R. ; Clark, L. C. / Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer : An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. In: BJU International. 2003 ; Vol. 91, No. 7. pp. 608-612.
@article{54faa62975fa42ddb044c59bcb0d640d,
title = "Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial",
abstract = "OBJECTIVE: To present the results (to January 1996, the end of blinded treatment) of the Nutritional Prevention of Cancer (NPC) Trial, a randomized trial of selenium (200 μg daily) designed to test the hypothesis that selenium supplementation (SS) could reduce the risk of recurrent nonmelanoma skin cancer among 1312 residents of the Eastern USA. MATERIALS AND METHODS: Original secondary analyses of the NPC to 1993 showed striking inverse associations between SS and prostate cancer incidence. A subsequent report revealed that this effect was accentuated among men with the lowest baseline plasma selenium concentrations. The effects of treatment overall and within subgroups of baseline prostate-specific antigen (PSA) and plasma selenium concentrations were examined using incidence rate ratios and Cox proportional hazards models. RESULTS: SS continued to significantly reduce the overall incidence (relative risk and 95{\%} confidence interval) of prostate cancer (0.51, 0.29-0.87). The protective effect of SS appeared to be confined to those with a baseline PSA level of ≤4 ng/mL (0.35, 0.13-0.87), although the interaction of baseline PSA and treatment was not statistically significant. Participants with baseline plasma selenium concentrations only in the lowest two tertiles (< 123.2 ng/mL) had significant reductions in prostate cancer incidence. A significant interaction between baseline plasma selenium and treatment was detected. CONCLUSION: To the end of the blinded treatment the NPC trial continued to show a significant protective effect of SS on the overall incidence of prostate cancer, although the effect was restricted to those with lower baseline PSA and plasma selenium concentrations.",
keywords = "Chemoprevention, Incidence, Prostate cancer, PSA, Risk, Selenium",
author = "Duffield-Lillico, {A. J.} and Dalkin, {B. L.} and Reid, {M. E.} and Turnbull, {B. W.} and Slate, {E. H.} and Jacobs, {Elizabeth T} and Marshall, {J. R.} and Clark, {L. C.}",
year = "2003",
month = "5",
doi = "10.1046/j.1464-410X.2003.04167.x",
language = "English (US)",
volume = "91",
pages = "608--612",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer

T2 - An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial

AU - Duffield-Lillico, A. J.

AU - Dalkin, B. L.

AU - Reid, M. E.

AU - Turnbull, B. W.

AU - Slate, E. H.

AU - Jacobs, Elizabeth T

AU - Marshall, J. R.

AU - Clark, L. C.

PY - 2003/5

Y1 - 2003/5

N2 - OBJECTIVE: To present the results (to January 1996, the end of blinded treatment) of the Nutritional Prevention of Cancer (NPC) Trial, a randomized trial of selenium (200 μg daily) designed to test the hypothesis that selenium supplementation (SS) could reduce the risk of recurrent nonmelanoma skin cancer among 1312 residents of the Eastern USA. MATERIALS AND METHODS: Original secondary analyses of the NPC to 1993 showed striking inverse associations between SS and prostate cancer incidence. A subsequent report revealed that this effect was accentuated among men with the lowest baseline plasma selenium concentrations. The effects of treatment overall and within subgroups of baseline prostate-specific antigen (PSA) and plasma selenium concentrations were examined using incidence rate ratios and Cox proportional hazards models. RESULTS: SS continued to significantly reduce the overall incidence (relative risk and 95% confidence interval) of prostate cancer (0.51, 0.29-0.87). The protective effect of SS appeared to be confined to those with a baseline PSA level of ≤4 ng/mL (0.35, 0.13-0.87), although the interaction of baseline PSA and treatment was not statistically significant. Participants with baseline plasma selenium concentrations only in the lowest two tertiles (< 123.2 ng/mL) had significant reductions in prostate cancer incidence. A significant interaction between baseline plasma selenium and treatment was detected. CONCLUSION: To the end of the blinded treatment the NPC trial continued to show a significant protective effect of SS on the overall incidence of prostate cancer, although the effect was restricted to those with lower baseline PSA and plasma selenium concentrations.

AB - OBJECTIVE: To present the results (to January 1996, the end of blinded treatment) of the Nutritional Prevention of Cancer (NPC) Trial, a randomized trial of selenium (200 μg daily) designed to test the hypothesis that selenium supplementation (SS) could reduce the risk of recurrent nonmelanoma skin cancer among 1312 residents of the Eastern USA. MATERIALS AND METHODS: Original secondary analyses of the NPC to 1993 showed striking inverse associations between SS and prostate cancer incidence. A subsequent report revealed that this effect was accentuated among men with the lowest baseline plasma selenium concentrations. The effects of treatment overall and within subgroups of baseline prostate-specific antigen (PSA) and plasma selenium concentrations were examined using incidence rate ratios and Cox proportional hazards models. RESULTS: SS continued to significantly reduce the overall incidence (relative risk and 95% confidence interval) of prostate cancer (0.51, 0.29-0.87). The protective effect of SS appeared to be confined to those with a baseline PSA level of ≤4 ng/mL (0.35, 0.13-0.87), although the interaction of baseline PSA and treatment was not statistically significant. Participants with baseline plasma selenium concentrations only in the lowest two tertiles (< 123.2 ng/mL) had significant reductions in prostate cancer incidence. A significant interaction between baseline plasma selenium and treatment was detected. CONCLUSION: To the end of the blinded treatment the NPC trial continued to show a significant protective effect of SS on the overall incidence of prostate cancer, although the effect was restricted to those with lower baseline PSA and plasma selenium concentrations.

KW - Chemoprevention

KW - Incidence

KW - Prostate cancer

KW - PSA

KW - Risk

KW - Selenium

UR - http://www.scopus.com/inward/record.url?scp=0038244793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038244793&partnerID=8YFLogxK

U2 - 10.1046/j.1464-410X.2003.04167.x

DO - 10.1046/j.1464-410X.2003.04167.x

M3 - Article

VL - 91

SP - 608

EP - 612

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 7

ER -